Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.

Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjö A, Gorgoulis V, Höfler G, Jung A, Kotsinas A, Laurent-Puig P, López-Ríos F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E.

Oncologist. 2011;16(4):467-78. doi: 10.1634/theoncologist.2010-0429. Epub 2011 Mar 26.

2.

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme.

Dequeker E, Ligtenberg MJ, Vander Borght S, van Krieken JH.

Virchows Arch. 2011 Aug;459(2):155-60. doi: 10.1007/s00428-011-1094-x. Epub 2011 Jun 24.

PMID:
21701884
3.

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.

Tack V, Ligtenberg MJ, Tembuyser L, Normanno N, Vander Borght S, Han van Krieken J, Dequeker EM.

Oncologist. 2015 Mar;20(3):257-62. doi: 10.1634/theoncologist.2014-0382. Epub 2015 Feb 5.

4.

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.

Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL.

J Transl Med. 2015 Sep 3;13:287. doi: 10.1186/s12967-015-0655-1.

5.

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.

Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken JH, Dequeker EM.

J Mol Diagn. 2014 May;16(3):371-7. doi: 10.1016/j.jmoldx.2014.01.003. Epub 2014 Mar 14.

PMID:
24631467
6.

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.

Dijkstra JR, Heideman DA, Meijer GA, Boers JE, 't Hart NA, Diebold J, Hirschmann A, Hoefler G, Winter G, Miltenberger-Miltenyi G, Pereira SV, Richman SD, Quirke P, Rouleau EL, Guinebretiere JM, Tejpar S, Biesmans B, van Krieken JH.

Virchows Arch. 2013 Jan;462(1):39-46. doi: 10.1007/s00428-012-1356-2. Epub 2012 Dec 15.

PMID:
23242173
7.

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.

Deans ZC, Tull J, Beighton G, Abbs S, Robinson DO, Butler R.

Genet Test Mol Biomarkers. 2011 Nov;15(11):777-83. doi: 10.1089/gtmb.2010.0239. Epub 2011 Aug 18.

PMID:
21851273
8.

Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.

Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, Schönbrunner ER, Shahbazian M, Edsjö A, Hoefler G, Jung A, Kotsinas A, Gorgoulis VG, López-Ríos F, de Stricker K, Rouleau E, Biesmans B, van Krieken JH.

J Mol Diagn. 2012 May-Jun;14(3):187-91. doi: 10.1016/j.jmoldx.2012.01.002. Epub 2012 Mar 10.

PMID:
22414609
9.

Setting future standards for KRAS testing in colorectal cancer.

van Krieken H, Tol J.

Pharmacogenomics. 2009 Jan;10(1):1-3. doi: 10.2217/14622416.10.1.1. No abstract available.

10.

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A.

Virchows Arch. 2008 Nov;453(5):417-31. doi: 10.1007/s00428-008-0665-y. Epub 2008 Sep 18. Review. Erratum in: Virchows Arch. 2009 Feb;454(2):233-5.

PMID:
18802721
11.

Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group.

PLoS One. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013.

12.

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.

Feigelson HS, Goddard KA, Johnson MA, Funk KC, Rahm AK, Kauffman TL, Chitale DA, Le Marchand L, Richards CS.

BMC Res Notes. 2012 Apr 25;5:196. doi: 10.1186/1756-0500-5-196.

13.

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.

Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC.

Mod Pathol. 2011 Aug;24(8):1090-100. doi: 10.1038/modpathol.2011.60. Epub 2011 Apr 22.

14.

[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].

Enlund F, Helenius G, Palmqvist R, Edsjö A, Sundström M.

Lakartidningen. 2010 Feb 3-9;107(5):255-9. Swedish. No abstract available.

PMID:
20297566
15.

KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.

Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M.

Cytopathology. 2011 Dec;22(6):358-64. doi: 10.1111/j.1365-2303.2010.00812.x. Epub 2010 Oct 4.

PMID:
21029218
16.

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M, Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A.

PLoS One. 2011;6(12):e29146. doi: 10.1371/journal.pone.0029146. Epub 2011 Dec 21.

17.

EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.

Thunnissen E, Bovée JV, Bruinsma H, van den Brule AJ, Dinjens W, Heideman DA, Meulemans E, Nederlof P, van Noesel C, Prinsen CF, Scheidel K, van de Ven PM, de Weger R, Schuuring E, Ligtenberg M.

J Clin Pathol. 2011 Oct;64(10):884-92. doi: 10.1136/jclinpath-2011-200163.

PMID:
21947301
18.

KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.

Wang HL, Lopategui J, Amin MB, Patterson SD.

Adv Anat Pathol. 2010 Jan;17(1):23-32. doi: 10.1097/PAP.0b013e3181c6962f. Review.

PMID:
20032635
19.

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.

Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E.

Acta Gastroenterol Belg. 2010 Oct-Dec;73(4):497-503. Review.

PMID:
21299161
20.

Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.

Ross JS.

Arch Pathol Lab Med. 2012 Oct;136(10):1298-307. Epub 2012 Jan 24. Review.

PMID:
22272560

Supplemental Content

Support Center